HomepageDSKYF • OTCMKTS
add
Daiichi Sankyo
Vorige slotkoers
$Â 25,33
Dag-range
$Â 22,86 - $Â 26,15
Jaar-range
$Â 20,15 - $Â 44,64
Beurswaarde
46,39Â mld. USD
Gem. volume
32,59K
Koers/winst
-
Dividendrendement
-
Primaire beurs
TYO
In het nieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(JPY) | mrt 2025info | Wijziging j-o-j |
---|---|---|
Opbrengst | 518,69Â mld. | 21,07% |
Bedrijfskosten | 340,74Â mld. | 11,02% |
Netto inkomsten | 87,15Â mld. | 134,49% |
Netto winstmarge | 16,80 | 93,55% |
Winst per aandeel | — | — |
EBITDA | 101,59Â mld. | 207,39% |
Effectief belastingtarief | -8,09% | — |
Balans
Totale activa
Totale passiva
(JPY) | mrt 2025info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 639,84Â mld. | -1,13% |
Totale activa | 3,46Â bln. | -0,14% |
Totale passiva | 1,83Â bln. | 3,39% |
Totaal aandelenvermogen | 1,62 bln. | — |
Uitstaande aandelen | 1,87 mld. | — |
Koers-boekwaardeverhouding | 0,03 | — |
Rendement op activa | 6,06% | — |
Rendement op kapitaal | 12,12% | — |
Kasstroom
Nettomutatie in liquide middelen
(JPY) | mrt 2025info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | 87,15Â mld. | 134,49% |
Operationele kasstroom | 72,12Â mld. | 140,65% |
Kasstroom uit beleggingen | -32,93Â mld. | 48,06% |
Kasstroom uit financiering | -58,51Â mld. | -1.424,12% |
Nettomutatie in liquide middelen | -42,31Â mld. | -116,34% |
Vrije kasstroom | 70,33Â mld. | 737,15% |
Over
Daiichi Sankyo Company, Limited is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. It achieved JPY 1,278 billion in revenue in 2022. The company owns the American pharmaceutical company American Regent.
Daiichi Sankyo, Inc. began operating in the U.S. in 2006. It is the U.S. subsidiary of Daiichi Sankyo Company, Limited, and a member of the Daiichi Sankyo Group. The organization, which includes U.S. commercial operations and global clinical development, is headquartered in Basking Ridge, New Jersey.
Daiichi Sankyo Europe, GmbH, the European subsidiary, is headquartered in Munich, Germany. The organization is responsible for development and manufacturing for 12 European countries.
Daiichi Sankyo Company, Limited is a full member of the European Federation of Pharmaceutical Industries and Associations and of the International Federation of Pharmaceutical Manufacturers and Associations. Wikipedia
CEO
Opgericht
1899
Hoofdvestiging
Website
Werknemers
18.726